UBS AM
KURA icon

UBS AM’s Kura Oncology KURA Stock Holding History

UBS AM’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Sell
122,645
-1,508
-1% -$14.2K ﹤0.01% 2237
2026
Q1 		$1.01M Buy
124,153
+17,264
+16% +$148K ﹤0.01% 2338
2025
Q4 		$1.11M Sell
106,889
-3,877
-4% -$40.7K ﹤0.01% 2108
2025
Q3 		$980K Sell
110,766
-78,954
-42% -$563K ﹤0.01% 2018
2025
Q2 		$1.09M Buy
189,720
+37,588
+25% +$230K ﹤0.01% 2368
2025
Q1 		$1M Buy
152,132
+20,414
+15% +$159K ﹤0.01% 2304
2024
Q4 		$1.15M Buy
131,718
+9,050
+7% +$130K ﹤0.01% 2305
2024
Q3 		$2.4M Sell
122,668
-2,436
-2% -$49.4K ﹤0.01% 1950
2024
Q2 		$2.58M Buy
125,104
+38,438
+44% +$790K ﹤0.01% 1859
2024
Q1 		$1.85M Buy
86,666
+4,810
+6% +$93.5K ﹤0.01% 1720
2023
Q4 		$1.18M Hold
81,856
– – ﹤0.01% 1943
2023
Q3 		$747K Buy
81,856
+41,887
+105% +$425K ﹤0.01% 2122
2023
Q2 		$489K Hold
39,969
– – ﹤0.01% 2334
2023
Q1 		$489K Sell
39,969
-5,950
-13% -$74.2K ﹤0.01% 2334
2022
Q4 		$570K Hold
45,919
– – ﹤0.01% 2127
2022
Q3 		$627K Sell
45,919
-294,543
-87% -$4.54M ﹤0.01% 2239
2022
Q2 		$6.24M Sell
340,462
-10,069
-3% -$145K ﹤0.01% 1135
2022
Q1 		$5.64M Sell
350,531
-21,219
-6% -$306K ﹤0.01% 1304
2021
Q4 		$5.2M Sell
371,750
-11,385
-3% -$184K ﹤0.01% 1398
2021
Q3 		$7.18M Sell
383,135
-9,528
-2% -$180K ﹤0.01% 1221
2021
Q2 		$8.19M Buy
392,663
+92,687
+31% +$2.3M ﹤0.01% 1188
2021
Q1 		$8.48M Buy
299,976
+40,660
+16% +$1.29M ﹤0.01% 1134
2020
Q4 		$8.47M Buy
259,316
+220,616
+570% +$7.75M ﹤0.01% 1114
2020
Q3 		$1.19M Buy
38,700
+460
+1% +$10.2K ﹤0.01% 1771
2020
Q2 		$623K Buy
38,240
+22,724
+146% +$328K ﹤0.01% 2027
2020
Q1 		$154K Sell
15,516
-8,277
-35% -$94.7K ﹤0.01% 2347
2019
Q4 		$327K Buy
23,793
+121
+0.5% +$1.79K ﹤0.01% 2350
2019
Q3 		$359K Buy
+23,672
New +$421K ﹤0.01% 2399

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

UBS AM's KURA Position: Q2 2026 in Review

UBS AM reduced its Kura Oncology (KURA) stake by 1.2% in Q2 2026, selling an estimated $14.2K and leaving 122,645 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2237.

UBS AM first reported a position in KURA in Q3 2019 and has held it in 28 quarters since. The position peaked at $8.48M in Q1 2021. 221 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • UBS AM held 122,645 shares of Kura Oncology worth $1.35M as of Q2 2026.
  • UBS AM sold 1,508 Kura Oncology shares in Q2 2026, an estimated $14.2K.
  • Kura Oncology made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2237 holding.
  • UBS AM first reported a position in Kura Oncology in Q3 2019 and has held it in 28 quarters since.
  • UBS AM's Kura Oncology position peaked at $8.48M in Q1 2021.
  • 221 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.